Cancer Research Targets  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 5363, July 1, 2008. doi: 10.1158/0008-5472.CAN-08-0035
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lovat, P. E.
Right arrow Articles by Redfern, C. P.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lovat, P. E.
Right arrow Articles by Redfern, C. P.F.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Increasing Melanoma Cell Death Using Inhibitors of Protein Disulfide Isomerases to Abrogate Survival Responses to Endoplasmic Reticulum Stress

Penny E. Lovat1, Marco Corazzari3, Jane L. Armstrong2, Shaun Martin1, Vittoria Pagliarini3, David Hill1, Anna M. Brown1, Mauro Piacentini3,4, Mark A. Birch-Machin1 and Christopher P.F. Redfern2

1 Dermatological Sciences, School of Clinical and Laboratory Sciences and 2 Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom; 3 L'Spallanzani, National Institute for Infectious Disease; and 4 University of Tor Vergata, Rome, Italy

Requests for reprints: Christopher Redfern, Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom. Phone: 44-191-246-4416; Fax: 44-191-246-4301; E-mail: chris.redfern{at}ncl.ac.uk.

Key Words: Apoptosis • Endoplasmic reticulum stress • protein disulfide isomerase inhibitors

Exploiting vulnerabilities in the intracellular signaling pathways of tumor cells is a key strategy for the development of new drugs. The activation of cellular stress responses mediated by the endoplasmic reticulum (ER) allows cancer cells to survive outside their normal environment. Many proteins that protect cells against ER stress are active as protein disulfide isomerases (PDI) and the aim of this study was to test the hypothesis that apoptosis in response to ER stress can be increased by inhibiting PDI activity. We show that the novel chemotherapeutic drugs fenretinide and velcade induce ER stress–mediated apoptosis in melanoma cells. Both stress response and apoptosis were enhanced by the PDI inhibitor bacitracin. Overexpression of the main cellular PDI, procollagen-proline, 2-oxoglutarate-4-dioxygenase β subunit (P4HB), resulted in increased PDI activity and abrogated the apoptosis-enhancing effect of bacitracin. In contrast, overexpression of a mutant P4HB lacking PDI activity did not increase cellular PDI activity or block the effects of bacitracin. These results show that inhibition of PDI activity increases apoptosis in response to agents which induce ER stress and suggest that the development of potent, small-molecule PDI inhibitors has significant potential as a powerful tool for enhancing the efficacy of chemotherapy in melanoma. [Cancer Res 2008;68(13):5363–8]




This article has been cited by other articles:


Home page
Mol. Cell. ProteomicsHome page
V. Gillardin, F. Silvestre, M. Dieu, E. Delaive, M. Raes, J.-P. Thome, and P. Kestemont
Protein Expression Profiling in the African Clawed Frog Xenopus laevis Tadpoles Exposed to the Polychlorinated Biphenyl Mixture Aroclor 1254
Mol. Cell. Proteomics, April 1, 2009; 8(4): 596 - 611.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. S. Hill, S. Martin, J. L. Armstrong, R. Flockhart, J. J. Tonison, D. G. Simpson, M. A. Birch-Machin, C. P.F. Redfern, and P. E. Lovat
Combining the Endoplasmic Reticulum Stress-Inducing Agents Bortezomib and Fenretinide as a Novel Therapeutic Strategy for Metastatic Melanoma
Clin. Cancer Res., February 15, 2009; 15(4): 1192 - 1198.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.